Insights and Key Takeaways from IPAC-RS NIF 2025
Proveris was honored to co-host the inaugural IPAC-RS Nasal Innovation Forum, where thought leaders across pharma, academia, instrumentation/automation, and device development gathered to discuss the future of nasal and inhaled therapeutics.
At the event, Maria Smith, Director of Applications and Business Development at Proveris Laboratories, delivered a talk on “Sniffing Out the Standards: Making Sense of Evolving Nasal Spray Testing”—exploring how optimized actuation and method design can de-risk early development and ensure regulatory success.
Conference Takeaways (Maria’s Insights)
“There is growing enthusiasm surrounding the nasal drug delivery landscape, with significant projected growth driven by ongoing research into nose-to-brain delivery and the repurposing of existing therapies for intranasal administration.
Navigating the regulatory landscape for nasal product approval is complex, with multiple potential pathways to consider. Partnering with trusted experts like Proveris, who have a proven track record of working effectively with regulatory authorities, is often key to identifying the most efficient path to approval and achieving long-term success.
Continued advancement in predictive and experimental models is critical to supporting the efficient and effective development of nasal products.”
— Maria Smith, Director of Applications and Business Development, Proveris Laboratories
What It Means for the Industry
The conference underscored a clear message: nasal drug delivery is entering a new era — one defined by rapid scientific progress, more ambitious therapeutic targets, and the need for rigorous, validated methods that regulators can trust.
From nose-to-brain research and vaccine delivery to the repurposing of small molecules, the opportunities are expanding — but so is the complexity. Success depends on integrating reliable, reproducible testing methods that can keep pace with innovation.
This is where Proveris plays a pivotal role. As the partner of choice for leading developers, our combination of automation, predictive modeling, and validated laboratory studies bridges early discovery with regulatory confidence.
Maria’s Closing Reflection
“As the Director of Applications and Business Development, I am energized by these emerging trends. Having worked extensively in this field, I’ve witnessed remarkable progress — but I also recognize there’s so much more to discover.
At Proveris, we are uniquely positioned to help our partners navigate this evolving landscape and drive meaningful innovation where it matters most.”
— Maria Smith, Proveris Laboratories
Request Maria’s Presentation. Get the full slide deck that inspired the discussion at IPAC-RS NIF.
Connect With Our Experts
Let’s discuss how Proveris can help advance your next nasal or inhalation program.
Building Confidence in Every Actuation
Explore Our Technologies
Learn More About Our Services